Trobix Bio Raises $3M in Equity Funding

Trobix Bio, a Netanya, Israel-based biotechnology company developing microbiome oncology therapeutics, raised $3M in Equity funding.

The round was led by Chartered Group.

The company intends to use the funds for the development of its products and proprietary platform technology, which addresses the gastrointestinal side effects of oncology treatments and other gastrointestinal diseases impacted by the microbiome. 

Led by CEO Dr. Adi Elkeles, Tobix Bio is a biotech company that has developed technology to develop orally administered cancer supportive care therapeutics to reduce life-threatening side effects associated with oncology therapeutics. Its products may enable physicians to complete oncology treatments at optimal doses while improving cancer patients’ quality of life. The technology converges computational, synthetic, and synthetic biology technologies in a proprietary way to engineer phages as medicines that reprogram, with precision, targeted microbiome bacteria, resulting in a durable therapeutic effect. 

TBX201 is an orally available capsule designed to specifically alter the gut microbiome to reduce the incidence and severity of severe diarrhea caused by irinotecan. Irinotecan is a first-line chemotherapy drug for the treatment of several metastatic cancer indications; however, its clinical use in over 100,000 patients annually is associated with life-threatening toxicity and treatment interruptions for many patients.